These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31628571)

  • 21. Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
    Baumgart DC; Le Berre C
    N Engl J Med; 2021 Sep; 385(14):1302-1315. PubMed ID: 34587387
    [No Abstract]   [Full Text] [Related]  

  • 22. [Managing inflammatory bowel disease in the biologics era: treating beyond symptoms is not sufficient].
    Peyrin-Biroulet L
    Rev Prat; 2014 Nov; 64(9):1207-9. PubMed ID: 25638855
    [No Abstract]   [Full Text] [Related]  

  • 23. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
    Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
    Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 in IBD: The experience of a single tertiary IBD center.
    Rizzello F; Calabrese C; Salice M; Calandrini L; Privitera H; Melotti L; Peruzzi G; Dussias N; Belluzzi A; Scaioli E; Decorato A; Siniscalchi A; Filippone E; Laureti S; Rottoli M; Poggioli G; Gionchetti P
    Dig Liver Dis; 2021 Mar; 53(3):271-276. PubMed ID: 33451910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of ustekinumab and vedolizumab in management of extra intestinal manifestations in inflammatory bowel disease.
    Katsanos KH; Fousekis FS; Armuzzi A
    Dig Liver Dis; 2023 Feb; 55(2):149-150. PubMed ID: 36319583
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases.
    Felice C; Pugliese D; Papparella LG; Pizzolante F; Onori E; Gasbarrini A; Rapaccini GL; Guidi L; Armuzzi A
    Expert Rev Clin Immunol; 2018 Sep; 14(9):751-759. PubMed ID: 30118354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?
    Dreesen E; Gils A
    J Crohns Colitis; 2017 Aug; 11(8):903-904. PubMed ID: 28333273
    [No Abstract]   [Full Text] [Related]  

  • 29. Allergy to Hevea latex.
    Pumphrey RS
    Clin Exp Immunol; 1994 Dec; 98(3):358-60. PubMed ID: 7994899
    [No Abstract]   [Full Text] [Related]  

  • 30. Biologic therapy in inflammatory bowel disease.
    Loftus EV
    Gastroenterol Clin North Am; 2014 Sep; 43(3):xv-xvii. PubMed ID: 25110264
    [No Abstract]   [Full Text] [Related]  

  • 31. Practical Aspects of Biological Throught Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis.
    Rosas J; Martín-López M; Otón T; Balsa A; Calvo-Alén J; Sanmartí R; Tornero J; Carmona L
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 2):378-385. PubMed ID: 30385295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
    Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR
    Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.
    Adar T; Faleck D; Sasidharan S; Cushing K; Borren NZ; Nalagatla N; Ungaro R; Sy W; Owen SC; Patel A; Cohen BL; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2019 Apr; 49(7):873-879. PubMed ID: 30773667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?
    Papamichael K; Osterman MT; Siegel CA; Melmed GY; Dubinsky MC; Colombel JF; Hanauer SB; Cheifetz AS
    Gastroenterology; 2018 Mar; 154(4):1201-1202. PubMed ID: 29432749
    [No Abstract]   [Full Text] [Related]  

  • 35. Current and emerging therapeutic targets for IBD.
    Neurath MF
    Nat Rev Gastroenterol Hepatol; 2017 May; 14(5):269-278. PubMed ID: 28144028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?
    D'Amico F; Peyrin-Biroulet L; Danese S; Fiorino G
    Curr Opin Pharmacol; 2020 Dec; 55():141-150. PubMed ID: 33254032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
    Papamichael K; Cheifetz AS
    Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.
    Murias S; Magallares L; Albizuri F; Pascual-Salcedo D; Dreesen E; Mulleman D
    Ther Drug Monit; 2017 Aug; 39(4):370-378. PubMed ID: 28703718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.
    Panaccione R; Steinhart AH; Bressler B; Khanna R; Marshall JK; Targownik L; Afif W; Bitton A; Borgaonkar M; Chauhan U; Halloran B; Jones J; Kennedy E; Leontiadis GI; Loftus EV; Meddings J; Moayyedi P; Murthy S; Plamondon S; Rosenfeld G; Schwartz D; Seow CH; Williams C; Bernstein CN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1680-1713. PubMed ID: 30853616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immediate and delayed reactions to radiocontrast media: is there an allergic mechanism?
    Brockow K
    Immunol Allergy Clin North Am; 2009 Aug; 29(3):453-68. PubMed ID: 19563991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.